In Vitro Fertilisation

Department of Health written question – answered on 6th April 2017.

Alert me about debates like this

Photo of Lord Alton of Liverpool Lord Alton of Liverpool Crossbench

To ask Her Majesty’s Government, with reference to paragraph 2.8 of the minutes of 9 March 2017 of the Licence Committee of the Human Fertilisation and Embryology Authority (HFEA) regarding babies born following pronuclear transfer between embryos, what procedures are in place to (1) identify whether a child born following pronuclear transfer is born with (a) a mitochondrial disease, (b) a genetic or epigenetic abnormality, (c) a birth defect, or (d) some other adverse outcome, (2) notify the HFEA in cases of any such adverse outcome, and (3) identify any such adverse outcome and notify the HFEA where consent for follow-up has not been granted.

Photo of Lord O'Shaughnessy Lord O'Shaughnessy The Parliamentary Under-Secretary of State for Health, Lord in Waiting (HM Household) (Whip)

The Human Fertilisation and Embryology Authority (HFEA) has advised that, as set out in Guidance Note 33 of the Authority’s code of practice, centres carrying out mitochondrial donation are required to have documented processes in place setting out how the health of children born from mitochondrial donation will be followed up. A copy of Guidance Note 33 is attached.

If the centre becomes aware that any child born as a result of mitochondrial donation has a mitochondrial disease, birth defect, genetic abnormality or if there has been any other adverse outcome, the centre must report this to the HFEA in accordance with the adverse incidents requirements set out in Guidance Note 27 of the code of practice. A copy of Guidance Note 27 is attached.

Guidance Note 33 (PDF Document, 449.25 KB)
Guidance Note 27 (PDF Document, 395.06 KB)

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.